论文部分内容阅读
目的探讨应用重组人生长激素 (γ-h GH)治疗儿童生长激素缺乏症 (GHD)的临床疗效、安全性及其临床价值。方法分别选择GHD儿童 66例 ,正常对照组儿童 3 5例。 GHD组给予γ-h GH 0 .1U/(kg· d) ,疗程 3个月。观察用药后生长速率、血清胰岛素样生长因子 -1(IGF-1)、血清胰岛素样生长因子结合蛋白 3 (IGFBP-3 )等指标的变化。结果治疗后 3个月时 GHD组生长速率由 (2 .8± 0 .7)cm/a增至 (13 .6± 3 .5 ) cm/a(P<0 .0 1) ;该药对患儿无明显副作用。 GHD组血清 IGF-1、IGFBP-3及骨转换指标均明显低于正常对照组 (P<0 .0 1) ,治疗后血清生长因子及骨转换生化指标均有明显提高 ,与治疗前比较有显著性差异 (P<0 .0 1)。结论 1γ-h GH治疗GHD近期疗效显著 ,且安全可靠 ;2检测血清 IGF -1和 IGFBP-3将有助于儿童 GHD的正确诊断 ;3血清骨转换生化指标对早期预测r-h GH疗效具有明显优势
Objective To investigate the clinical efficacy, safety and clinical value of recombinant human growth hormone (γ-h GH) in the treatment of children with growth hormone deficiency (GHD). Methods Sixty-six children with GHD and thirty-five children with normal control were selected. GHD group was given γ-h GH 0 .1U / (kg · d) for 3 months. The changes of growth rate, serum insulin-like growth factor-1 (IGF-1) and serum insulin-like growth factor binding protein 3 (IGFBP-3) were observed. Results The growth rate of GHD group increased from (2. 8 ± 0. 7) cm / a to (13.6 ± 3.5) cm / a (P <0.01) at 3 months after treatment. No obvious side effects in children. Serum levels of IGF-1, IGFBP-3 and bone turnover in GHD group were significantly lower than those in normal control group (P <0.01), serum biochemical markers of bone growth and bone turnover were significantly increased after treatment Significant difference (P <0. 01). Conclusions 1γ-h GH treatment of GHD recent significant effect, and safe and reliable; 2 detection of serum IGF-1 and IGFBP-3 will contribute to the correct diagnosis of GHD in children; 3 serum bone turnover biochemical markers of early prediction of r-h GH has obvious advantages